Targets › FLT3
42 programs from 38 companies in 133 trials: 58 Phase 2, 56 Phase 1, 19 Phase 3; Oncology, Gastroenterology, Hematology; next expected readout Nov 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. (UniProt, P36888)
Open in Phaseline: the race on FLT3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Jiao Tong University School of Medicine | Fludarabine, Busulfan and Melphalan (Flu-Bu-Mel) Dual alkylating agents with purine nucleoside analog; busulfan and melphalan are DNA-alkyl | FLT3, TP53 | Phase 3 | Acute Myeloid Leukemia; Toxicities | Dec 2026 |
| Swedish Orphan Biovitrum | Pacritinib Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor | JAK2, FLT3, ACVR1, IRAK1 | Phase 3 | Primary Myelofibrosis; VEXAS; Myelofibrosis; Acute Myeloid Leukemia … | Dec 2026 |
| Daiichi Sankyo | Pexidartinib Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor | CSF1R, FLT3, KIT | Phase 3 | Tenosynovial Giant Cell Tumor; Neurofibroma, Plexiform | Mar 2027 |
| Daiichi Sankyo | Quizartinib Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor | CSF1R, FLT3, KIT, PDGFRB, PDGFRA | Phase 3 | Leukemia; Acute Myeloid Leukemia; Hepatic Impairment; Acute Myeloid Leukemia, Adult … | May 2027 |
| Jiangsu HengRui Medicine | Famitinib Stem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | KIT, FLT1, FLT3, PDGFRB, PDGFRA | Phase 3 | Cervical Cancer; Triple-Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Neoplasm … | May 2027 |
| Sunshine Lake Pharma | Clifutinib Besylate (HEC73543) FLT3-ITD inhibitor | FLT3 | Phase 3 | Leukemia, Acute Myeloid (AML); Acute Myeloid Leukemia, Adult | Nov 2027 |
| Roche | Sorafenib Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | RAF1, PDGFRB, KIT, FLT3, BRAF | Phase 3 | Unresectable Hepatocellular Carcinoma; AML (Acute Myeloid Leukemia); Locally Advanced Thyroid Gland Carcinoma; Hepatocellular Carcinoma … | – |
| M.D. Anderson Cancer Center | Sunitinib Malate Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Renal Cell Carcinoma; Malignant Neoplasms of Urinary Tract; Prostate Cancer | Dec 2026 |
| National Cancer Institute (NCI) | Sunitinib Malate Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Advanced Lymphoma; Metastatic Pancreatic Neuroendocrine Tumor | Dec 2026 |
| Ryvu Therapeutics | MEN1703 (SEL24, Dapolsertib hydrochloride) Dual inhibitor of PIM kinases and FLT3 | PIM1, PIM2, PIM3, FLT3 | Phase 2 | Non-Hodgkin Lymphoma, B-cell | Dec 2026 |
| Nanfang Hospital, Southern Medical University | Donafenib multi-targeted tyrosine kinase inhibitor | BRAF, FLT3, RET | Phase 2 | Unresectable Hepatocellular Carcinoma | Dec 2026 |
| Weill Medical College of Cornell University | CDX-301 Tyrosine-protein kinase receptor FLT3 agonist | FLT3 | Phase 2 | Breast Cancer | Dec 2026 |
| Canadian Cancer Trials Group | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Advanced Rare Tumours | Dec 2026 |
| University of Miami | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Gastrointestinal Stromal Tumors | Dec 2026 |
| National Cancer Institute (NCI) | Sorafenib Tosylate Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | RAF1, PDGFRB, KIT, FLT3, BRAF | Phase 2 | Gastrointestinal Stromal Tumor; Acute Myeloid Leukemia; Advanced Malignant Solid Neoplasm | Mar 2027 |
| Sarcoma Alliance for Research through Collaboration | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Gastrointestinal Stromal Tumors | Jun 2027 |
| Fudan University | Sitravatinib Small molecule inhibitor of receptor tyrosine kinases | PDGFRA, KIT, RET, FLT3 | Phase 2 | Metastatic Breast Cancer | Jun 2027 |
| American Society of Clinical Oncology | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Lymphoma, Non-Hodgkin | Dec 2027 |
| Bai-Rong Xia | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Ovary Cancer | Dec 2027 |
| Memorial Sloan Kettering Cancer Center | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Osteosarcoma | Mar 2028 |
| Theradex | Pacritinib Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor | JAK2, FLT3, ACVR1, IRAK1 | Phase 2 | Leukemia, Myelomonocytic, Chronic | Jul 2028 |
| Novartis | Midostaurin Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor | FLT3, KIT, PDGFRB, PDGFRA, PRKD3 | Phase 2 | FLT3-mutated Acute Myeloid Leukemia; AML/MDS; Acute Myeloid Leukemia | May 2029 |
| Yu Wang | Donafenib Multikinase inhibitor targeting BRAF, VEGFR, and FLT3 | BRAF, VEGFR, FLT3 | Phase 2 | Thyroid Cancer | – |
| West China Hospital | Donafenib Multi-targeted tyrosine kinase inhibitor targeting RAF, VEGFR, and FLT3 | RAF, VEGFR, FLT3 | Phase 2 | Locally Advanced Thyroid Gland Carcinoma | – |
| Aptose Biosciences | Tuspetinib (HM43239) FLT3 inhibitor | FLT3 | Phase 1 | Leukemia, Myeloid, Acute | Nov 2026 |
| Bristol-Myers Squibb | Fedratinib Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor | FLT3, JAK2 | Phase 1 | Primary Myelofibrosis; Acute Myeloid Leukemia | Nov 2026 |
| Emory University | MRX-2843 FLT3/MerTK inhibitor | FLT3, MERTK | Phase 1 | Advanced Lung Non-Small Cell Carcinoma | Dec 2026 |
| University of Southern California | CDX-301 Tyrosine-protein kinase receptor FLT3 agonist | FLT3 | Phase 1 | Anatomic Stage IV Breast Cancer AJCC v8 | Jan 2027 |
| Hemogenyx Pharmaceuticals | Anti-FLT3 CAR-T cells Anti-FLT3 chimeric antigen receptor T-cell therapy | FLT3 | Phase 1 | Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | Jan 2027 |
| Ashutosh Kumar Tewari | CDX-301 Tyrosine-protein kinase receptor FLT3 agonist | FLT3 | Phase 1 | Prostate Cancer | Jan 2027 |
| Etnova Therapeutics | ETN101 Multiple tyrosine kinase inhibitor targeting FLT3, KIT, VEGFR2, and PDGFRB | FLT3, KIT, VEGFR2, PDGFRB | Phase 1 | Hepatocellular Carcinoma | Mar 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | TAA05 Cell Injection Anti-FLT3 CAR-T cell therapy | FLT3 | Phase 1 | Acute Myeloid Leukemia | Jun 2027 |
| Hangzhou Polymed Biopharmaceuticals | HPB-092 FLT3 and IRAK4 inhibitor | FLT3, IRAK4 | Phase 1 | Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) | Jun 2027 |
| State University of New York at Buffalo | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Carcinoma, Renal Cell | Jul 2027 |
| University of Colorado, Denver | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Osteosarcoma | Aug 2027 |
| Dana-Farber Cancer Institute | CDX-301 Tyrosine-protein kinase receptor FLT3 agonist | FLT3 | Phase 1 | Melanoma | Dec 2027 |
| Rabin Medical Center | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Solid Tumors Refractory to Standard Therapy | Jan 2028 |
| University of Texas Southwestern Medical Center | CDX-301 Tyrosine-protein kinase receptor FLT3 agonist | FLT3 | Phase 1 | HER2-negative Breast Cancer | Apr 2028 |
| Astellas | Gilteritinib Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor | FLT3, AXL | Phase 1 | Acute Myeloid Leukemia (AML); Non-small Cell Lung Cancer (NSCLC); AML (Acute Myeloid Leukemia); Acute Myeloid Leukemia … | Jul 2028 |
| National Cancer Institute (NCI) | Zotiraciclib Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor | CDK1, CDK2, CDK7, CDK9, FLT3 | Phase 1 | Brain Tumor | Aug 2028 |
| Cullinan Therapeutics | CLN-049 FLT3 x CD3 bispecific T cell engager | FLT3, CD3E | Phase 1 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | Dec 2029 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Furuitinib FLT3 inhibitor | FLT3 | Phase 1 | Advanced Malignancies | – |
Acute Myeloid Leukemia (22) Hepatocellular Carcinoma (5) Primary Myelofibrosis (3) Prostate Cancer (3) Acute Myeloid Leukemia (AML) (3) Acute Myeloid Leukemia, Adult (2) Chronic Myelomonocytic Leukemia (2) Osteosarcoma (2) Thyroid Cancer (2) Myelofibrosis (2) Breast Cancer (2) Gastrointestinal Stromal Tumors (2)
small molecule (25), mixed (10), antibody (4), other (2), protein or peptide (1)
National Cancer Institute (NCI) (3) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) Daiichi Sankyo (2) Sunshine Lake Pharma (1) Ryvu Therapeutics (1) Canadian Cancer Trials Group (1) Bristol-Myers Squibb (1) University of Texas Southwestern Medical Center (1) Novartis (1) Cullinan Therapeutics (1) Dana-Farber Cancer Institute (1) Aptose Biosciences (1) University of Southern California (1) Fudan University (1) Etnova Therapeutics (1) Memorial Sloan Kettering Cancer Center (1) Ashutosh Kumar Tewari (1) Yu Wang (1) Swedish Orphan Biovitrum (1) Emory University (1)
KIT (19) PDGFRB (17) PDGFRA (15) CSF1R (13) BRAF (4) JAK2 (3) RAF1 (2) RET (2) VEGFR (2) ACVR1 (2) IRAK1 (2) PIM1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.